A recent study shows that healthy sleep patterns were associated with a reduced risk of heart disease and stroke by about one-third, even among those at high genetic risk.

Ubrogepant is the first drug in the calcitonin-related peptide receptor antagonist class approved for the acute treatment of migraine.

In the study published by Suzanne M. Bertisch et al. and entitled Nighttime Sleep Duration, Fragmentation and Daily Sleep Quality and Risk of Migraine, they attempt to test the hypotheses that insufficient duration, high fragmentation and poor sleep quality are temporarily associated with the onset of migraine on the day immediately following the...